| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Xia Qiu, Sheng-Li Cheng, Yan-Hui Liu, Yu Li, Rui Zhang, Nan-Nan Li and Zheng Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China (General Program) |
82104525 |
| Natural Science Foundation of the Jiangsu Higher Education Institutions of China |
21KJB360009 |
| Natural Science Foundation of Jiangsu Normal University |
20XSRX002 |
|
| Corresponding Author |
Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com |
| Key Words |
Non-alcoholic fatty liver disease; Fecal microbiota transplantation; Randomized controlled trial; Mechanism; Efficacy |
| Core Tip |
There are several reviews contributed to the role of gut microbiome in the pathophysiology, therapeutic potential and clinical trials for non-alcoholic fatty liver disease (NAFLD). However, no consensus is available in the literature about the clinical efficacy of fecal microbiota transplantation (FMT) on NAFLD. This is a first review to summary recent randomized controlled trials for evaluating the effects of FMT on blood lipid profile, liver function, histological changes and other parameters in patients with NAFLD, discussed its therapeutic mechanism, and proposed the obstacles and prospect of FMT in future trials. |
| Publish Date |
2024-02-26 13:28 |
| Citation |
Qiu XX, Cheng SL, Liu YH, Li Y, Zhang R, Li NN, Li Z. Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect. World J Gastroenterol 2024; 30(8): 833-842 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i8/833.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i8.833 |
